CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) to participate in Raymond James & Associates’ 45th Annual Institutional Investors Conference. The company will present on March 6, 2024, focusing on precision medicine for transplant patients.
02/27/2024 - 04:05 PM
BRISBANE, Calif. --(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the company will be participating in the upcoming Raymond James & Associates’ 45th Annual Institutional Investors Conference.
CareDx’s management is scheduled to present on Wednesday, March 6, 2024, at 9:50 a.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the “Investors” section of the company’s website at investors.CareDx.com .
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California , is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit www.CareDx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227235923/en/
CareDx, Inc.
aczene@caredx.com
Investor Relations
investor@caredx.com
Source: CareDx, Inc.
When is CareDx, Inc. participating in the Raymond James & Associates’ 45th Annual Institutional Investors Conference?
CareDx, Inc. is participating in the conference on March 6, 2024.
What is the focus of CareDx, Inc. at the conference?
CareDx, Inc. will focus on precision medicine solutions for transplant patients at the conference.
Where can interested parties access the live audio webcast of CareDx, Inc.'s presentation?
Interested parties can access the live audio webcast on the 'Investors' section of the company's website at investors.CareDx.com.
CDNA Rankings
#5231 Ranked by Stock Gains
CDNA Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Technology, Medical Specialties, Health Care and Social Assistance, Medical Laboratories
Country
US
City
South San Francisco
About CDNA
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
